Synopsis
Synopsis
0
CEP/COS
0
KDMF
0
VMF
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. Bs 100 141
2. Bs-100-141
3. Bs100141
4. Estulic
5. Guanfacine
6. Guanfacine Monohydrochloride
7. Hydrochloride, Guanfacine
8. Lon798
9. Monohydrochloride, Guanfacine
10. Tenex
1. 29110-48-3
2. Guanfacine Hcl
3. Tenex
4. Intuniv
5. Guanfacine (hydrochloride)
6. N-carbamimidoyl-2-(2,6-dichlorophenyl)acetamide Hydrochloride
7. Estulic
8. Bs 100-141
9. 29520-14-7
10. N-(aminoiminomethyl)-2,6-dichlorobenzeneacetamide Hydrochloride
11. Spd503
12. N-amidino-2-(2,6-dichlorophenyl)acetamide Hydrochloride
13. N-amidino-2-(2,6-dichlorophenyl)acetamide Monohydrochloride
14. Guafacine Hydrochloride
15. Bs-100-141
16. Benzeneacetamide, N-(aminoiminomethyl)-2,6-dichloro-, Monohydrochloride
17. Spd 503
18. Mls000069745
19. Pml56a160o
20. Smr000058453
21. 29110-48-3 (hcl)
22. Dsstox_cid_25157
23. Dsstox_rid_80708
24. Dsstox_gsid_45157
25. Connexyn
26. Lon 798
27. N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide;hydrochloride
28. Cas-29520-14-7
29. Guanfacinehcl
30. Tenex (tn)
31. Guanfacinehydrochloride
32. Sr-01000075893
33. Ncgc00015469-05
34. Einecs 249-443-3
35. N-(aminoiminomethyl)-2,6-dichlorophenylacetamide Monohydrochloride
36. Unii-pml56a160o
37. Spd-503
38. Prestwick_740
39. Guanfacine Hydrochloride (jan/usp)
40. Intuniv (tn)
41. Mfcd00798230
42. Guanfacine Hydrochloride [usan:usp:jan]
43. Opera_id_1928
44. N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide Hydrochloride
45. Benzeneacetamide, N-(aminoiminomethyl)-2,6-dichloro-, Hydrochloride (1:1)
46. G 1043
47. Schembl41681
48. Mls001077329
49. Mls002222252
50. [(2,6-dichlorophenyl)acetyl]guanidine Hydrochloride
51. Chebi:5559
52. Chembl1200494
53. Dtxsid2045157
54. Schembl15603414
55. Hms1569c19
56. Hms3747e15
57. Pharmakon1600-01505435
58. Bcp21710
59. N-(aminoiminomethyl)-2,6-dichloro-benzeneacetamide Hydrochloride
60. Tox21_110159
61. Tox21_500519
62. Guanfacine Hydrochloride [mi]
63. Nsc759121
64. S4693
65. Guanfacine Hydrochloride [jan]
66. Akos015966858
67. Akos030242245
68. Tox21_110159_1
69. Ccg-213439
70. Ccg-220339
71. Cs-1254
72. Guanfacine Hydrochloride [usan]
73. Lp00519
74. Guanfacine Hydrochloride [mart.]
75. Guanfacine Hydrochloride [vandf]
76. Guanfacine Hydrochloride [usp-rs]
77. Guanfacine Hydrochloride [who-dd]
78. Ncgc00015469-09
79. Ncgc00093914-01
80. Ncgc00093914-02
81. Ncgc00180965-01
82. Ncgc00261204-01
83. As-12253
84. Hy-17416
85. Guanfacine Hydrochloride, >=98% (hplc)
86. Bs100-141
87. Db-047525
88. Eu-0100519
89. Ft-0630546
90. Ft-0698181
91. G0414
92. Guanfacine Hydrochloride [orange Book]
93. D00606
94. Guanfacine Hydrochloride [usp Monograph]
95. T72238
96. A826918
97. J-017395
98. S-877503
99. Sr-01000075893-1
100. Sr-01000075893-3
101. Sr-01000075893-6
102. Q27286641
103. N-carbamimidoyl-2-(2,6-dichlorophenyl)-acetamide Hydrochloride
104. Guanfacine Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
105. Guanfacine Hydrochloride, United States Pharmacopeia (usp) Reference Standard
106. N-[bis(azanyl)methylidene]-2-[2,6-bis(chloranyl)phenyl]ethanamide Hydrochloride
| Molecular Weight | 282.5 g/mol |
|---|---|
| Molecular Formula | C9H10Cl3N3O |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 1 |
| Rotatable Bond Count | 2 |
| Exact Mass | 280.988945 g/mol |
| Monoisotopic Mass | 280.988945 g/mol |
| Topological Polar Surface Area | 81.5 Ų |
| Heavy Atom Count | 16 |
| Formal Charge | 0 |
| Complexity | 256 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 4 | |
|---|---|
| Drug Name | Guanfacine hydrochloride |
| Drug Label | Tenex (guanfacine hydrochloride) is a centrally acting antihypertensive with 2-adrenoceptor agonist properties in tablet form for oral administration. The chemical name of Tenex (guanfacine hydrochloride) is N-amidino- 2-(2,6-dichlorophenyl) acetam... |
| Active Ingredient | Guanfacine hydrochloride |
| Dosage Form | Tablet, extended release; Tablet |
| Route | oral; Oral |
| Strength | eq 4mg base; eq 2mg base; 1mg; eq 1mg base; eq 3mg base; 4mg; 2mg; 3mg |
| Market Status | Tentative Approval; Prescription |
| Company | Twi Pharms; Epic Pharma; Teva Pharms Usa; Sandoz; Watson Labs; Actavis Elizabeth; Amneal Pharm; Mylan |
| 2 of 4 | |
|---|---|
| Drug Name | Tenex |
| PubMed Health | Guanfacine (By mouth) |
| Drug Classes | Antihypertensive, Cardiovascular Agent, Central Nervous System Agent |
| Drug Label | Tenex (guanfacine hydrochloride) is a centrally acting antihypertensive with 2-adrenoceptor agonist properties in tablet form for oral administration. The chemical name of Tenex (guanfacine hydrochloride) is N-amidino- 2-(2,6-dichlorophenyl) acetam... |
| Active Ingredient | Guanfacine hydrochloride |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | eq 2mg base; eq 1mg base |
| Market Status | Prescription |
| Company | Promius Pharma |
| 3 of 4 | |
|---|---|
| Drug Name | Guanfacine hydrochloride |
| Drug Label | Tenex (guanfacine hydrochloride) is a centrally acting antihypertensive with 2-adrenoceptor agonist properties in tablet form for oral administration. The chemical name of Tenex (guanfacine hydrochloride) is N-amidino- 2-(2,6-dichlorophenyl) acetam... |
| Active Ingredient | Guanfacine hydrochloride |
| Dosage Form | Tablet, extended release; Tablet |
| Route | oral; Oral |
| Strength | eq 4mg base; eq 2mg base; 1mg; eq 1mg base; eq 3mg base; 4mg; 2mg; 3mg |
| Market Status | Tentative Approval; Prescription |
| Company | Twi Pharms; Epic Pharma; Teva Pharms Usa; Sandoz; Watson Labs; Actavis Elizabeth; Amneal Pharm; Mylan |
| 4 of 4 | |
|---|---|
| Drug Name | Tenex |
| PubMed Health | Guanfacine (By mouth) |
| Drug Classes | Antihypertensive, Cardiovascular Agent, Central Nervous System Agent |
| Drug Label | Tenex (guanfacine hydrochloride) is a centrally acting antihypertensive with 2-adrenoceptor agonist properties in tablet form for oral administration. The chemical name of Tenex (guanfacine hydrochloride) is N-amidino- 2-(2,6-dichlorophenyl) acetam... |
| Active Ingredient | Guanfacine hydrochloride |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | eq 2mg base; eq 1mg base |
| Market Status | Prescription |
| Company | Promius Pharma |
Intuniv is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6 17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective.
Intuniv must be used as a part of a comprehensive ADHD treatment programme, typically including psychological, educational and social measures.
Adrenergic alpha-2 Receptor Agonists
Compounds that bind to and activate ADRENERGIC ALPHA-2 RECEPTORS. (See all compounds classified as Adrenergic alpha-2 Receptor Agonists.)
Antihypertensive Agents
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)
C02AC02
NDC Package Code : 12598-9508
Start Marketing Date : 2014-03-31
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING
GDUFA
DMF Review : Reviewed
Rev. Date : 2015-02-24
Pay. Date : 2014-06-19
DMF Number : 28312
Submission : 2014-05-19
Status : Active
Type : II
NDC Package Code : 46016-2911
Start Marketing Date : 2022-03-24
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (50kg/50kg)
Marketing Category : BULK INGREDIENT

GDUFA
DMF Review : Reviewed
Rev. Date : 2013-02-26
Pay. Date : 2013-02-05
DMF Number : 8590
Submission : 1990-06-12
Status : Active
Type : II
NDC Package Code : 53296-0024
Start Marketing Date : 2010-03-17
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (75kg/75kg)
Marketing Category : BULK INGREDIENT

GDUFA
DMF Review : Reviewed
Rev. Date : 2014-10-27
Pay. Date : 2014-07-15
DMF Number : 28443
Submission : 2014-08-04
Status : Active
Type : II

GDUFA
DMF Review : Reviewed
Rev. Date : 2014-08-01
Pay. Date : 2014-07-29
DMF Number : 8661
Submission : 1990-07-12
Status : Active
Type : II
Registration Number : 227MF10293
Registrant's Address : Calle Dulcinea, s/n 28805 Alcala De Henares Madrid Spain
Initial Date of Registration : 2015-12-24
Latest Date of Registration :
NDC Package Code : 53069-1150
Start Marketing Date : 2024-09-24
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 36431
Submission : 2021-12-23
Status : Active
Type : II
Registration Number : 307MF10107
Registrant's Address : No. 11, Weiqi Road, Hangzhou Bay Shangyu Economic and Technological Development Area, Shaoxing City, Zhejiang Province, China
Initial Date of Registration : 2025-08-21
Latest Date of Registration :

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39404
Submission : 2024-01-11
Status : Active
Type : II
Registration Number : 307MF10102
Registrant's Address : No. 6, Weiwu Road, Hangzhou Gulf Shangyu Economic and Technological Development Zone, Zhejiang, China
Initial Date of Registration : 2025-08-06
Latest Date of Registration :

GDUFA
DMF Review : Reviewed
Rev. Date : 2020-10-14
Pay. Date : 2020-09-08
DMF Number : 34653
Submission : 2020-03-26
Status : Active
Type : II
Date of Issue : 2025-09-19
Valid Till : 2028-07-27
Written Confirmation Number : WC-0062
Address of the Firm :
NDC Package Code : 53747-096
Start Marketing Date : 2020-03-26
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

GDUFA
DMF Review : Reviewed
Rev. Date : 2016-11-18
Pay. Date : 2016-08-23
DMF Number : 28049
Submission : 2014-03-07
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 4784
Submission : 1982-12-06
Status : Inactive
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
GDUFA
DMF Review : Complete
Rev. Date : 2016-11-18
Pay. Date : 2016-08-23
DMF Number : 28049
Submission : 2014-03-07
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2013-02-26
Pay. Date : 2013-02-05
DMF Number : 8590
Submission : 1990-06-12
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 36431
Submission : 2021-12-23
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2015-02-24
Pay. Date : 2014-06-19
DMF Number : 28312
Submission : 2014-05-19
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2014-08-01
Pay. Date : 2014-07-29
DMF Number : 8661
Submission : 1990-07-12
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 4784
Submission : 1982-12-06
Status : Inactive
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 4985
Submission : 1983-04-22
Status : Inactive
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2014-10-27
Pay. Date : 2014-07-15
DMF Number : 28443
Submission : 2014-08-04
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2020-10-14
Pay. Date : 2020-09-08
DMF Number : 34653
Submission : 2020-03-26
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39404
Submission : 2024-01-11
Status : Active
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC Package Code : 12598-9508
Start Marketing Date : 2014-03-31
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 63190-0250
Start Marketing Date : 2008-12-16
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 63190-0390
Start Marketing Date : 2008-12-16
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 65372-1177
Start Marketing Date : 2014-03-04
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 53296-0024
Start Marketing Date : 2010-03-17
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (75kg/75kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 46016-2912
Start Marketing Date : 2013-07-01
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (50kg/50kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 46016-2911
Start Marketing Date : 2022-03-24
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (50kg/50kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 53069-0080
Start Marketing Date : 1995-01-01
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 53069-1150
Start Marketing Date : 2024-09-24
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 53747-096
Start Marketing Date : 2020-03-26
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]About the Company : More than 35 years of dedication to quality, service and pursuit of excellence, CHEMO was founded by Hugo Sigman, M.D., and Silvia Gold, Biochemist, in Spain (Barcelona), in 1977, ...

About the Company : Guangzhou Tosun Pharmaceutical was founded in 1999, which mainly focuses on importation & exportation of Active Pharmaceutical Ingrediants, Chemical Raw Materials, Intermediate, Ex...

About the Company : Harman Finochem Limited is a leading India-based Pharmaceutical Company which specializes in the manufacture and export of more than 45 Active Pharmaceutical Ingredients (APls) of ...

About the Company : Jubilant Life Sciences Limited, is an integrated global pharmaceutical and life sciences company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmace...

About the Company : Procos S.p.A. is a wholly owned subsidiary of the Japanese company, CBC Co. Ltd Group, specializing in the development, scale-up and production of Active Pharmaceutical Ingredients...

About the Company : Torrent Pharma is part of 3 billion USD Torrent group; we are leading conglomerate from India, having presence across 40 countries including USA, Brazil, Europe, and Mexico & India...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
85
PharmaCompass offers a list of Guanfacine API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Guanfacine manufacturer or Guanfacine supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Guanfacine manufacturer or Guanfacine supplier.
PharmaCompass also assists you with knowing the Guanfacine API Price utilized in the formulation of products. Guanfacine API Price is not always fixed or binding as the Guanfacine Price is obtained through a variety of data sources. The Guanfacine Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Tenex manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Tenex, including repackagers and relabelers. The FDA regulates Tenex manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Tenex API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Tenex manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Tenex supplier is an individual or a company that provides Tenex active pharmaceutical ingredient (API) or Tenex finished formulations upon request. The Tenex suppliers may include Tenex API manufacturers, exporters, distributors and traders.
click here to find a list of Tenex suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Tenex DMF (Drug Master File) is a document detailing the whole manufacturing process of Tenex active pharmaceutical ingredient (API) in detail. Different forms of Tenex DMFs exist exist since differing nations have different regulations, such as Tenex USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Tenex DMF submitted to regulatory agencies in the US is known as a USDMF. Tenex USDMF includes data on Tenex's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Tenex USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Tenex suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Tenex Drug Master File in Japan (Tenex JDMF) empowers Tenex API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Tenex JDMF during the approval evaluation for pharmaceutical products. At the time of Tenex JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Tenex suppliers with JDMF on PharmaCompass.
A Tenex written confirmation (Tenex WC) is an official document issued by a regulatory agency to a Tenex manufacturer, verifying that the manufacturing facility of a Tenex active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Tenex APIs or Tenex finished pharmaceutical products to another nation, regulatory agencies frequently require a Tenex WC (written confirmation) as part of the regulatory process.
click here to find a list of Tenex suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Tenex as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Tenex API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Tenex as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Tenex and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Tenex NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Tenex suppliers with NDC on PharmaCompass.
Tenex Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Tenex GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Tenex GMP manufacturer or Tenex GMP API supplier for your needs.
A Tenex CoA (Certificate of Analysis) is a formal document that attests to Tenex's compliance with Tenex specifications and serves as a tool for batch-level quality control.
Tenex CoA mostly includes findings from lab analyses of a specific batch. For each Tenex CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Tenex may be tested according to a variety of international standards, such as European Pharmacopoeia (Tenex EP), Tenex JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Tenex USP).